Press Releases and Events
PRESS RELEASES
Press Release | February 3, 2021
Press Release | January 6, 2021
Crinetics Announces 2021 Plans at J.P. Morgan Healthcare Conference
READ MORE
Press Release | November 23, 2020
Crinetics Pharmaceuticals to Participate in December Investor Conferences
READ MORE
Press Release | November 16, 2020
Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology
READ MORE
Press Release | November 13, 2020
Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for Treatment of Acromegaly
READ MORE
Press Release | November 6, 2020
Third Quarter 2020 Financial Results and Corporate Update
READ MORE
Press Release | October 26, 2020
ACROBAT Edge Study of Paltusotine in Acromegaly Met Endpoint
READ MORE
Press Release | September 21, 2020
Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism
READ MORE
Press Release | September 4, 2020
New Data from Paltusotine and ACTH Antagonist Development Programs- European Congress of Endocrinology
READ MORE
Press Release | September 3, 2020
Crinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D., to Board of Directors
READ MORE
SIGN UP
WEBCAST
PRESENTATIONTransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
You are now leaving Crinetics.com
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
